The estimated Net Worth of Rosana Kapeller Libermann is at least $151 Tausend dollars as of 7 June 2021. Rosana Libermann owns over 1,000 units of Schrodinger stock worth over $20,580 and over the last 5 years he sold SDGR stock worth over $0. In addition, he makes $130,226 as Independent Director at Schrodinger.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rosana Libermann SDGR stock SEC Form 4 insiders trading
Rosana has made over 1 trades of the Schrodinger stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 1,000 units of SDGR stock worth $4,340 on 7 June 2021.
The largest trade he's ever made was exercising 1,000 units of Schrodinger stock on 7 June 2021 worth over $4,340. On average, Rosana trades about 167 units every 0 days since 2020. As of 7 June 2021 he still owns at least 1,000 units of Schrodinger stock.
You can see the complete history of Rosana Libermann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rosana Kapeller-Libermann biography
Dr. Rosana Kapeller-Libermann M.D. Ph.D. serves as Independent Director of the Company. Dr. Kapeller-Libermann has served as president and chief executive officer of Rome Therapeutics, Inc., a therapeutics company, since April 2019. She has also served as an entrepreneur in residence at GV, a venture capital investment arm of Alphabet Inc. since November 2018. Prior to that, Dr. Kapeller-Libermann served as founding chief scientific officer of Nimbus Therapeutics, or Nimbus, a biotechnology company, from February 2010 to March 2018. Prior to joining Nimbus, she served as vice president of research at Aileron Therapeutics, Inc., a biopharmaceutical company, from August 2005 to September 2009. Dr. Kapeller-Libermann received an M.D. from Universidade do Estado do Rio de Janeiro and a Ph.D. in Molecular and Cellular Physiology from Tufts University. Kapeller-Libermann’s scientific experience in the field of drug discovery and extensive experience working with life sciences companies qualifies her to serve on our board of directors.
What is the salary of Rosana Libermann?
As the Independent Director of Schrodinger, the total compensation of Rosana Libermann at Schrodinger is $130,226. There are 10 executives at Schrodinger getting paid more, with Dr. Ramy Farid Ph.D. having the highest compensation of $1,010,921.
How old is Rosana Libermann?
Rosana Libermann is 56, he's been the Independent Director of Schrodinger since 2019. There are 8 older and 13 younger executives at Schrodinger. The oldest executive at Schrodinger, Inc. is Dr. Richard A. Friesner, 68, who is the Co-Founder, Scientific Advisory Chairman and Director.
What's Rosana Libermann's mailing address?
Rosana's mailing address filed with the SEC is C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK, NY, 10036.
Insiders trading at Schrodinger
Over the last 5 years, insiders at Schrodinger have traded over $1,009,056,149 worth of Schrodinger stock and bought 838,235 units worth $14,249,995 . The most active insiders traders include & Melinda Gates Foundation ..., David E Schrodinger Equity ... und Michael Lynton. On average, Schrodinger executives and independent directors trade stock every 10 days with the average trade being worth of $2,459,207. The most recent stock trade was executed by Kenneth Patrick Lorton on 6 March 2024, trading 5,574 units of SDGR stock currently worth $24,191.
What does Schrodinger do?
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
What does Schrodinger's logo look like?
Complete history of Rosana Libermann stock trades at Schrodinger
Schrodinger executives and stock owners
Schrodinger executives and other stock owners filed with the SEC include:
-
Dr. Ramy Farid Ph.D.,
CEO, Pres & Director -
Yvonne Tran Esq.,
Exec. VP, Chief Legal Officer & Sec. -
Dr. Karen Akinsanya Ph.D.,
Exec. VP, Chief Biomedical Scientist and Head of Discovery R&D -
Ramy Farid,
President, Chief Executive Officer, Director -
Cony D cruz,
Executive Vice President - Chief Business Officer -
Yvonne Tran,
Executive Vice President, Chief Legal Officer -
Dr. Richard A. Friesner,
Co-Founder, Scientific Advisory Chairman and Director -
Richard Friesner,
Independent Director -
Nancy Thornberry,
Independent Director -
Gary Sender,
Independent Director -
Rosana Kapeller-Libermann,
Independent Director -
Timothy Wright,
Independent Director -
Shane Brauner,
Senior Vice President, Chief Information Officer -
Kenneth Lorton,
Senior Vice President, Chief Technology Officer -
Karen Akinsanya,
Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D -
Robert Abel,
Executive Vice President - science -
Jorg Weiser,
Executive Vice President, Managing Director -
Jennifer Daniel,
Chief Human Resource Officer, Senior Vice President -
Joel Lebowitz,
Executive Vice President, Chief Financial Officer -
Michael Lynton,
Independent Chairman of the Board of Directors -
Michelle Byington,
VP of HR -
Jennifer Mayer Daniel,
Sr. VP & Chief HR Officer -
Jaren Irene Madden,
Sr. VP of Investor Relations & Corp. Communications -
Shane Brauner,
Exec. VP & Chief Information Officer -
Kenneth Patrick Lorton,
Exec. VP & CTO -
Prof. William Goddard III,
Co-Founder & Scientific Advisor -
Charles Ardai,
10% owner -
Geoffrey Craig Porges,
EVP & CFO -
David E Shaw,
10% owner -
Gary L Ginsberg,
Director -
Jeffrey Chodakewitz,
Director -
& Melinda Gates Foundation ...,
10% owner -
David E Schrodinger Equity ...,
-
James E Deerfield Mgmt Iv, ...,
-
Jenny Herman,
SVP & Controller -
Arun Oberoi,
Director -
Margaret Dugan,
Chief Medical Officer